No needles, no injections - topical application that absorbs in second
Your provider will usually look at your BMI range and overall health to decide if Wegovy may be a good fit
Potential mechanisms include: Reducing oxidative stress Improving mitochondrial efficiency Supporting cellular repair Clinical evidence is still evolving, and use should be cautious and individualized
We cover proper reconstitution, injection technique, rotation sites, and storage for both compounds
doi: 10.1172/JCI186652, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 47
#FDAApproval #ObesityMedicine #GLP1 #Semaglutide #WeightManagement To view or add a comment, sign in BREAKING: The future of diabetes and obesity management just got more exciting Novo Nordisk has officially submitted CagriSema (semaglutide 2.4 mg + cagrilintide 2.4 mg) to the FDAmarking the first GLP-1 + amylin fixed-dose combination for chronic weight management